Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × Cisplatin × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 206 Squamous Cell Carcinoma of Head and Neck 123 Head and Neck Neoplasms 113 Lung Neoplasms 105 Esophageal Neoplasms 80 Stomach Neoplasms 76 Uterine Cervical Neoplasms 56 Esophageal Squamous Cell Carcinoma 55 Urinary Bladder Neoplasms 51 Breast Neoplasms 50 Nasopharyngeal Carcinoma 47 Small Cell Lung Carcinoma 40 Carcinoma, Squamous Cell 39 Pancreatic Neoplasms 34 Neoplasms 33 Neoplasm Metastasis 31 Biliary Tract Neoplasms 30 Cholangiocarcinoma 29 Ovarian Neoplasms 27 Oropharyngeal Neoplasms 27 Adenocarcinoma Of Esophagus 27 Mesothelioma, Malignant 26 Lymphoma 23 Adenocarcinoma of Lung 23 Carcinoma, Ovarian Epithelial 20 Carcinoma 19 Recurrence 18 Lymphoma, Large B-Cell, Diffuse 18 Lymphoma, Non-Hodgkin 16 Laryngeal Neoplasms 16

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡